Roots Analysis has announced the addition of “Monkeypox Market: Focus on Therapeutics, Vaccines and Diagnostic Kits, 2023-2035” report to its list of offerings.
Given the increase in research and development activity in this domain and the substantial financial assistance provided by public funding institutes, the monkeypox therapeutics / vaccines and diagnostic kits market is projected to grow at a steady pace in the near future. The recent rise in the incidence of the monkeypox disease, also known as Mpox, has compelled both industry players and regional government authorities to undertake active initiatives in order to control the spread of the disease
Key Market Insights
25+ monkeypox therapeutics and vaccines are currently approved / under development
More than 20% of the aforementioned candidates are approved or have been granted expanded access for the treatment / prevention of monkeypox. Further, 70% of the total candidates are in preclinical stages of development. It is also worth noting that ~65% of the candidates in development pipeline are biologics.
Over 120 developers claim to provide diagnostic kits for monkeypox virus detection
Interestingly, nearly 65% of the diagnostic kit providers are based in Asia-Pacific and rest of the world. Notably, around 50% of the total players engaged in this space are mid-sized firms. Additionally, over 75% of monkeypox diagnostic kits use polymerase chain reaction (PCR) as a detection method.
Partnership activity within this domain has grown at a CAGR of ~150%, between 2018 and 2022
More than 85% of the partnerships were inked in the year 2022, indicating the recent surge in interest of industry stakeholders in this domain. Further, majority of the deals were supply agreements (75%), and primarily focused on expanding their global reach.
More than 250 grants have been awarded for research related to monkeypox therapeutics, vaccines and diagnostic solutions
Close to 40% of the total amount was awarded under the R01 mechanism (which supports research projects). Further, microbiology / immunology / virology departments emerged as the key research departments, having received over 35% of the total grants.
Over 230 articles related to monkeypox therapeutics, vaccines and diagnostic kits have been published between 2018 and 2022
35% of the articles published in this domain were research papers, followed by review papers (12%). It is important to note that close to 90% of the total articles were published post-2020, highlighting the growing research activity in the recent years.
North America and Europe are anticipated to capture close to 95% share of the monkeypox therapeutics and vaccines market, by 2035
The monkeypox therapeutics / vaccines market’s evolution is likely to be driven by the rising need for novel drug candidates. In terms of type of product, vaccines are expected to occupy a larger share (99%) of the overall monkeypox therapeutics and vaccines market in 2035.
PCR Kits are anticipated to capture more than 70% share of the monkeypox diagnostic kits market, by 2035
In the long term, hospitals and clinics are likely to contribute to a majority share (~50%) of revenues as end users. Further, North America and Europe are anticipated to capture close to 70% share of the monkeypox diagnostic kits market.
To request a sample copy / brochure of this report, please visit
Key Questions Answered
- What are the factors driving the overall monkeypox market?
- Who are the key players engaged in the development of monkeypox therapeutics / vaccines, and diagnostic kits?
- How many therapeutics and vaccines are approved for the treatment and prevention of monkeypox?
- What is the count of monkeypox diagnostic kits that are currently available in the market?
- What are the partnership and collaboration trends observed in relation to monkeypox therapeutics / vaccines and diagnostic kits?
- Which segment, in terms of type of product, accounts for the largest monkeypox therapeutics / vaccines market share?
- Which type of diagnostic kit accounts for the largest monkeypox market share?
The financial opportunity within the within the monkeypox therapeutics / vaccines and diagnostic kits market has been analyzed across the following segments:
- Type of Product
- Bavarian Nordic
- Emergent BioSolutions
- KM Biologics
- SIGA Technologies
- Type of Kit
- Polymerase Chain Reaction (PCR) Detection Kits
- Antigen Detection Kits
- Antibody Detection Kits
- Type of End User
- Hospitals and Clinics
- Diagnostic Laboratories
- Other End Users
- Key Geographical Regions
- North America (US and Canada)
- Europe (UK, France, Germany, Spain, Italy, Rest of EU)
- Asia-Pacific (Japan and Australia)
- Rest of the World
The opinions and insights presented in the report were influenced by discussions held with multiple stakeholders in this domain. According to industry experts the monkeypox therapeutics / vaccines and diagnostic kits market is likely to grow over the coming years if the disease becomes a pandemic. The report features detailed transcripts of interviews held with the following industry stakeholders:
- Willy Tozoke Laou Man Cheong (Business Director, Hunan Runmei Gene Technology)
- John W Sharkey (Vice President, Business Development, GeoVax)
- Horace Lee (Sales Manager, Firegene)
- Alan Yu (Sales Manager, Hangzhou Testsea Biotechnology)
The research also includes detailed profiles of key players (listed below) engaged in the monkeypox therapeutics / vaccines and diagnostic kits markets; each profile features a brief overview of the company, details related to its product portfolio (therapeutics / vaccines or diagnostic kits), recent developments and an informed future outlook.
- Bavarian Nordic
- Emergent BioSolutions
- ACON Laboratories
- altona Diagnostics
- DNA Software
- Goldsite Diagnostics
- Hangzhou Testsea Biotechnology
- Jiangsu Bioperfectus Technologies
- Lansion Biotechnology
For additional details, please visit
You may also be interested in the following titles:
- Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
- 4D Bioprinting Market : Industry Trends and Global Forecasts, 2022-2035
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
+1 (415) 800 3415